J&J invests in experimental drugs as competitive threats loom
New York
JOHNSON & JOHNSON is investing in a collection of experimental drugs with blockbuster potential, treating widespread illnesses such as blood cancer and Alzheimer's disease, to help rise above looming competitive threats to its pharmaceutical business.
The world's biggest maker of health products said on Wednesday it plans to seek regulatory approval for more than 10 new drugs by 2019 with potential annual sales of more than US$1 billion apiece. That would help J&J regain some momentum in what has become its biggest division, whose drugs approved in the last few years are projected to lag behind its biggest rivals.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Australia’s retail sales volumes fall 0.4% in Q1
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore